Key result
Patients with the AGT GG genotype had significantly greater reductions in blood pressure in response to ACE inhibitors compared to AA or AG carriers (p=0.007 for systolic blood pressure).
Why the study?
Does the A-6G variant of the AGT gene affect blood pressure response to ACE inhibitors in mildly to moderately hypertensive subjects?
Cohort (n=509)
Does the A-6G variant of the AGT gene affect blood pressure response to ACE inhibitors in mildly to moderately hypertensive subjects?
p-value: p=0.007, 0.014, 0.027, 0.005
The A-6G variant of the AGT gene, specifically the GG genotype, is associated with a significantly greater blood pressure reduction in response to ACE inhibitors in hypertensive patients.
Hypothesis-generating for AGT genotyping to guide ACEI therapy; does not yet support clinical adoption.
INTRODUCTION: The polymorphic angiotensinogen (AGT) gene is one of the most promising candidates for essential hypertension. The aim of this study was to examine the association between the A-6G variant of the AGT gene and the blood pressure response to angiotensin-converting enzyme (ACE) inhibitors in hypertensive subjects. METHODS: Five hundred and nine mildly to moderately hypertensive subjects received ACE inhibitors for six weeks after a two-week run-in period. AGT genotyping was performed by direct polymerase chain reaction amplification and deoxyribonucleic acid (DNA) nucleotide sequencing from peripheral blood. RESULTS: The AA genotype, AG genotype, and GG genotype were present in 301 (59.1%), 186 (36.6%), and 22 (4.3%) of patients, respectively. As compared with patients carrying the AA or AG genotype, those carrying the GG genotype had significantly greater reductions in systolic blood pressure, diastolic blood pressure, pulse pressure and mean arterial pressure (p=0.007, 0.014, 0.027 and 0.005, respectively). Moreover, stepwise multiple linear regression analysis showed that the A-6G genotype was a significant predictor of systolic blood pressure and pulse pressure reductions (p=0.040 and 0.019, respectively). CONCLUSION: Our study indicates that the A-6G variant of the AGT gene may be an important determinant of interindividual variation in the response to ACE inhibitors.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2014) conducted a cohort in Mild to moderate hypertension (n=509). AGT gene A-6G variant (GG genotype) vs. AA or AG genotype was evaluated on Reductions in systolic blood pressure, diastolic blood pressure, pulse pressure and mean arterial pressure (p=0.007, 0.014, 0.027, 0.005). Patients with the AGT GG genotype had significantly greater reductions in blood pressure in response to ACE inhibitors compared to AA or AG carriers (p=0.007 for systolic blood pressure).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: